Therefore, ROR1 is a key driver of CSC characteristics in glioblastoma through cross-signaling networks, making it an attractive therapeutic target to overcome CSC-mediated tumor progression and resistance in glioblastoma. This evidence concerns the gene ROR1 and glioblastoma.